Gregory D. Lewis

Gregory D. Lewis

Auto-generated profile, based on publicly available information

Gregory D. Lewis

Heart and Vascular Institute, Mass General Brigham, Boston, MA (G.D.L.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2017 in JAMA
Verified
Journal Article
Open access
PDF file
GLGregory D. Lewis
Gregory D. Lewis
RMRajeev Malhotra
Rajeev Malhotra
AHAdrian F. Hernandez
Adrian F. Hernandez
SMSteven E. McNulty
Steven E. McNulty
ASAndrew Smith
Andrew Smith
FNfor the NHLBI Heart Failure Clinical Research Network
for the NHLBI Heart Failure Clinical Research Network
Iron deficiency is the most common nutritional deficiency worldwide, affecting more than 15% of the global population as of 20101 and approximately one-half of patients with symptomatic heart failure.2 The presence of iron deficiency in patients with heart failure, regardless of hemoglobin status, is associated with reduced functional capacity, poorer quality of life, and increased mortality.2,3

1 March 2015 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
BDBishnu P. Dhakal
Bishnu P. Dhakal
RMRajeev Malhotra
Rajeev Malhotra
RMRyan M. Murphy
Ryan M. Murphy
PPPaul P. Pappagianopoulos
Paul P. Pappagianopoulos
ABAaron L. Baggish
Aaron L. Baggish
GLGregory D. Lewis
Gregory D. Lewis
Background—: Exercise capacity as measured by peak oxygen uptake (V o 2 ) is similarly impaired in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). However, characterization of how each component of V o 2 changes in response to incremental exercise in HFpEF versus HFrEF has not been previously defined. We hypothesized that abnormally low peripheral o 2 extraction (arterio-mixed venous o 2 content difference, [C(a-v)o 2 ]) during exercise significantly contributes to impaired exercise capacity in HFpEF. Methods and Results—: We performed maximum incremental cardiopulmonary exercise testing with invasive hemodynamic monitoring on 104 patients with symptomatic NYHA II to IV heart failure (HFpEF, n=48, peak V o 2 =13.9±0.5 mL kg −1 min −1 , mean±SEM, and HFrEF, n=56, peak V o 2 =12.1±0.5 mL kg −1 min −1 ) and 24 control subjects (peak V o 2 27.0±1.7 mL kg −1 min −1 ). Peak exercise C(a-v)o 2 was lower in HFpEF compared with HFrEF (11.5±0.27 versus 13.5±0.34 mL/dL, respectively, P <0.0001), despite no differences in age, hemoglobin level, peak respiratory exchange ratio, Ca o 2 , or cardiac filling pressures. Peak C(a-v)o 2 and peak heart rate emerged as the leading predictors of peak V o 2 in HFpEF. Impaired peripheral o 2 extraction was the predominant limiting factor to exercise capacity in 40% of patients with HFpEF and was closely related to elevated systemic blood pressure during exercise ( r =0.49, P =0.0005). Conclusions—: In the first study to directly measure C(a-v)o 2 throughout exercise in HFpEF, HFrEF, and normals, we found that peak C(a-v)o 2 was a major determinant of exercise capacity in HFpEF. The important functional limitation imposed by impaired o 2 extraction may reflect intrinsic abnormalities in skeletal muscle or peripheral microvascular function, and represents a potential target for therapeutic intervention.

26 May 2010 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GLGregory D. Lewis
Gregory D. Lewis
LFLaurie Farrell
Laurie Farrell
MWMalissa J. Wood
Malissa J. Wood
MMMaryann Martinovic
Maryann Martinovic
ZAZoltan Arany
Zoltan Arany
RGRobert E. Gerszten
Robert E. Gerszten
Measurement by mass spectrometry of 200 blood metabolites reveals that individuals who are more fit respond more effectively to exercise, as shown by larger exercise-induced increase in glycerol.

1 August 2016 in JACC: Heart Failure
Verified
Journal Article
Closed access
RMRajeev Malhotra
Rajeev Malhotra
KBKristian Bakken
Kristian Bakken
Emilia D'EliaEmilia D'Elia
Emilia D'Elia
GLGregory D. Lewis
Gregory D. Lewis

9 January 2018 in Circulation
Verified
Journal Article
Closed access
PDF file
NHNicholas E. Houstis
Nicholas E. Houstis
AEAaron S. Eisman
Aaron S. Eisman
PPPaul P. Pappagianopoulos
Paul P. Pappagianopoulos
LWLuke Wooster
Luke Wooster
CBCole S. Bailey
Cole S. Bailey
GLGregory D. Lewis
Gregory D. Lewis
Background: Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. Methods: We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O 2 pathway) in each patient with HFpEF, identifying the defective steps that impair each one’s exercise capacity (peak Vo 2 ). We then quantified the functional significance of each O 2 pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect. Results: Peak Vo 2 was reduced by 34±2% (mean±SEM, P <0.001) in HFpEF compared with controls of similar age, sex, and body mass index. The vast majority (97%) of patients with HFpEF harbored defects at multiple steps of the O 2 pathway, the identity and magnitude of which varied widely. Two of these steps, cardiac output and skeletal muscle O 2 diffusion, were impaired relative to controls by an average of 27±3% and 36±2%, respectively ( P <0.001 for both). Due to interactions between a given patient’s defects, the predicted benefit of correcting any single one was often minor; on average, correcting a patient’s cardiac output led to a 7±0.5% predicted improvement in exercise intolerance, whereas correcting a patient’s muscle diffusion capacity led to a 27±1% improvement. At the individual level, the impact of any given O 2 pathway defect on a patient’s exercise capacity was strongly influenced by comorbid defects. Conclusions: Systematic analysis of the O 2 pathway in HFpEF showed that exercise capacity was undermined by multiple defects, including reductions in cardiac output and skeletal muscle diffusion capacity. An important source of disease heterogeneity stemmed from variation in each patient’s personal profile of defects. Personalized O 2 pathway analysis could identify patients most likely to benefit from treating a specific defect; however, the system properties of O 2 transport favor treating multiple defects at once, as with exercise training.

1 May 2018 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
AEAaron S. Eisman
Aaron S. Eisman
RSRavi V. Shah
Ravi V. Shah
BDBishnu P. Dhakal
Bishnu P. Dhakal
PPPaul P. Pappagianopoulos
Paul P. Pappagianopoulos
LWLuke Wooster
Luke Wooster
GLGregory D. Lewis
Gregory D. Lewis
Background: Single measurements of left ventricular filling pressure at rest lack sensitivity for identifying heart failure with preserved ejection fraction (HFpEF) in patients with dyspnea on exertion. We hypothesized that exercise hemodynamic measurements (ie, changes in pulmonary capillary wedge pressure [PCWP] indexed to cardiac output [CO]) may more sensitively differentiate HFpEF and non-HFpEF disease states, reflect aerobic capacity, and forecast heart failure outcomes in individuals with normal PCWP at rest. Methods and Results: We studied 175 patients referred for cardiopulmonary exercise testing with hemodynamic monitoring: controls (n=33), HFpEF with resting PCWP≥15 mm Hg (n=32), and patients with dyspnea on exertion with normal resting PCWP and left ventricular ejection fraction (DOE-nlrW; n=110). Across 1835 paired PCWP-CO measurements throughout exercise, we used regression techniques to define normative bounds of “PCWP/CO slope” in controls and tested the association of PCWP/CO slope with exercise capacity and composite cardiac outcomes (defined as cardiac death, incident resting PCWP elevation, or heart failure hospitalization) in the DOE-nlrW group. Relative to controls (PCWP/CO slope, 1.2±0.4 mm Hg/L/min), patients with HFpEF had a PCWP/CO slope of 3.4±1.9 mm Hg/L/min. We used a threshold (2 SD above the mean in controls) of 2 mm Hg/L/min to define abnormal. PCWP/CO slope >2 in DOE-nlrW patients was common (n=45/110) and was associated with reduced peak V o 2 ( P 2 mm Hg/L/min) is common in DOE-nlrW and predicts exercise capacity and heart failure outcomes. These findings suggest that current definitions of HFpEF based on single measures during rest are insufficient and that assessment of exercise PCWP/CO slope may refine early HFpEF diagnosis.